Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings

European Journal of Nuclear Medicine

Volumn 25, Issue 9, 1998, Pages 1277-1283

  Adams, Stefan ^a   Baum, Richard P ^a   Hertel, Andreas ^a   Schumm Draeger, Petra Maria ^a   Usadel, Klaus Henning ^a   Hör, Gustav ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

99mTc(V) DMSA; 111In DTPA D Phe1 pentetreotide; Medullary thyroid carcinoma; Metabolic and receptor imaging; Neuroendocrine tumours

Indexed keywords

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; SUCCIMER TC 99M; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ENCHONDROMA; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; LYMPH NODE METASTASIS; LYMPHADENITIS; MALE; MEDIASTINUM LYMPH NODE; METABOLISM; METASTASIS; PHEOCHROMOCYTOMA; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID MEDULLARY CARCINOMA;

CARCINOMA, MEDULLARY; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TECHNETIUM TC 99M DIMERCAPTOSUCCINIC ACID; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031668864     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050296     Document Type: Article

References (30)

1. Sipple JH. The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med 1961; 31: 163-166.
2. Williams ED, Pollock DJ. Multiple mucosal neuromata with endocrine tumours: a syndrome allied to von Recklinghausen's disease. J Pathol Bacteriol 1966; 91: 71-80.
3. Schröder S, Bocker W, Baisch H, et al. Prognostic factors in medullary thyroid carcinoma. Cancer 1988; 62; 806-816.
4. Woolner LB, Beahrs OH, Black BM, McConahey WM, Keating FR. Long-term survival rates. In: Hedinger CHR, ed. Thyroid cancer. Berlin Heidelberg New York: Springer; 1969: 326-330.
5. Grauer A, Blind E. Tumour markers for medullary thyroid carcinoma. Recent Results Cancer Res 1992; 125: 55-89.
6. De Lellis RA, Rule AH, Spiler I, et al. Calcitonin and carcinoembryonic antigen as tumour markers in medullary thyroid carcinoma. Am J Clin Pathol 1978; 51: 587-594.
7. Raue F, Winter J, Frank-Raue K, Lorenz D, Herfarth C, Ziegler R. Diagnostic procedure before reoperation in patients with medullary thyroid carcinoma. Horm Metab Res Suppl 1989; 21: 31-34.
8. Sandrock D, Blossey HC, Steinroeder M, Munz DL. Contribution of different scintigraphic techniques to the management of medullary thyroid carcinoma. Henry Ford Hosp Med J 1989; 37: 173-174.
9. Reiners C, Eilles C, Spiegel W, Becker W, Börner W. Immunoscintigraphy in medullary thyroid cancer using an I-123 or In-111-labelled monoclonal anti-CEA antibody fragment. Nuklearmedizin 1986; 25: 227-231.
10. 99mTc (V) dimercaptosuccinic acid (DMSA). Henry Ford Hosp Med J 1989; 37: 167-168.
11. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
12. Reubi JC, Krenning E, Lamberts SW, Kvols L. In vitro detection of somatostatin receptors in human tumours. Digestion 1993; 54: 76-83.
13. Kwekkeboom DJ, Reubi JC, Lamberts SW, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993; 76: 1413-1417.
14. Frank-Raue K, Bihl H, Dörr U, Buhr H, Ziegler R, Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol 1995; 42: 31-37.
15. Adams S, Baum RP, Adams M, et al. Zur klinischen Wertigkeit der Somatostatinrezeptorszintigraphie. Med Klin 1997; 92: 138-143.
16. Adams S, Baum RP, Adams M, et al. Intraoperative gamma probe detection of neuroendocrine tumours. J Nucl Med in press.
17. Guerra UP, Pizzocaro C, Terzi A, et al. New tracers for the imaging of the medullary carcinoma. Nucl Med Commun 1989; 10: 285-295.
18. Thomas CC, Cowan RJ, Albertson DA, Cooper MR. Detection of medullary carcinoma of the thyroid with I-131 MIBG. Clin Nucl Med 1994; 12: 1066-1068.
19. Bergholm U, Adami HO, Auer G, et al. Histopathologic characteristics and nuclear DNA content as prognostic factors in medullary thyroid carcinoma. A nationwide study in Sweden. Cancer 1989; 64: 135-142.
20. Busnardo B, Girelli ME, Simoini N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 1984; 53: 278-285.
21. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991; 64: 567-573.
22. Dörr U, Frank-Raue K, Raue F, et al. The potential value of somatostatin receptor scintigraphy in medullary thyroid carcinoma. Nucl Med Commun 1993; 14: 439-445.
23. 111 In-octreotide scintigraphy. Eur J Nucl Med 1992; 19: 599 (A).
24. Baudin E, Lumbroso J, Schlumberger M, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996; 37: 912-916.
25. Ohta H, Yamamoto K, Endo K. A new imaging agent for medullary carcinoma of the thyroid. J Nucl Med 1984; 25: 323-325.
26. 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur J Nucl Med 1996; 23: 1367-1371.
27. Eising EG, Farahati J, Bier D, Knust EJ, Reiners C. Somatostatin receptor scintigraphy in medullary thyroid cancer and in GEP and carcinoid tumours. Nuklearmedizin 1995; 34: 1-7.
28. 99mTc(V) DMSA in squamous carcinoma: a comparative study in humans and in an animal tumour model. Nucl Med Commun 1990; 11: 547-555.
29. 99mTc(V)-DMSA in lung metastasis of osteosarcoma. Ann Nucl Med 1989; 3: 37-40.
30. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin receptors and its analogs in the diagnosis and treatment of tumours. Endocr Rev 1991; 12: 450-482.